Microvascular endothelial function in subjects with type 2 diabetes and the effect of lipid-lowering therapy

Diabetic Medicine

Volumn 22, Issue 12, 2005, Pages 1670-1676

  Fegan, P Gerry ^a   Shore, A C ^a   Mawson, D ^a   Tooke, J E ^a   MacLeod, K M ^a  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

Author keywords

Endothelium; Iontophoresis; Lipids; Microvascular; Type 2 diabetes

Indexed keywords

ACETYLCHOLINE; C REACTIVE PROTEIN; CERIVASTATIN; FENOFIBRATE; NITROPRUSSIDE SODIUM; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEMOGRAPHY; DIABETIC MICROANGIOPATHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOTHELIUM INJURY; FEMALE; HEAT TREATMENT; HUMAN; HYPEREMIA; IONTOPHORESIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SKIN BLOOD FLOW; TREATMENT OUTCOME;

ADULT; AGED; ANTILIPEMIC AGENTS; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MICROCIRCULATION; MIDDLE AGED; PROCETOFEN; PYRIDINES;

EID: 30044446335     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2005.01719.x     Document Type: Article

References (53)

1. Jarrett RJ, Shipley MJ. Type 2 (non-insulin-dependent) diabetes mellitus and cardiovascular disease - putative association via common antecedents; further evidence from the Whitehall Study. Diabetologia 1988; 31: 737-740.
2. Heart Protection Study CG. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
3. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614-620.
4. West of Scotland Coronary Prevention Study (WOSCOPS) SG. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440-1445.
5. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Invest Circulation 1998; 98: 2513-2519.
6. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
7. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332: 481-487.
8. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89: 2519-2524.
9. Khan F, Litchfield SJ, Stonebridge PA, Belch JJ. Lipid-lowering and skin vascular responses in patients with hypercholesterolaemia and peripheral arterial obstructive disease. Vasc Med 1999; 4: 233-238.
10. Wang TD, Chen WJ, Lin JW, Cheng CC, Chen MF, Lee YT. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis 2003; 170: 315-323.
11. Evans M, Andersen RA, Graham J, Ellis GR, Morris K, Davies S et al. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation 2000; 101: 1773-1779.
12. Malik J, Melenovsky V, Wichterle D, Haas T, Simek J, Ceska R et al. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial - FAT). Cardiovasc Res 2001; 52: 290-298.
13. Bae JH, Bassenge E, Lee HJ, Park KR, Park CG, Park KY et al. Impact of postprandial hypertriglyceridemia on vascular responses in patients with coronary artery disease: effects of ACE inhibitors and fibrates. Atherosclerosis 2001; 158: 165-171.
14. Makimattila S, Liu ML, Vakkilainen J, Schlenzka A, Lahdenpera S, Syvanne M et al. Impaired endothelium-dependent vasodilation in type 2 diabetes. Relation to LDL size, oxidized LDL, and antioxidants. Diabetes Care 1999; 22: 973-981.
15. Morris SJ, Shore AC, Tooke JE. Responses of the skin microcirculation to acetylcholine and sodium nitroprusside in patients with NIDDM. Diabetologia 1995; 38: 1337-1344.
16. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1996; 27: 567-574.
17. Vakkilainen J, Makimattila S, Seppala-Lindroos A, Vehkavaara S, Lahdenpera S, Groop PH et al. Endothelial dysfunction in men with small LDL particles. Circulation 2000; 102: 716-721.
18. Sheu WH, Juang BL, Chen YT, Lee WJ. Endothelial dysfunction is not reversed by simvastatin treatment in type 2 diabetic patients with hypercholesterolemia. Diabetes Care 1999; 22: 1224-1225.
19. Tsunekawa T, Hayashi T, Kano H, Sumi D, Matsui-Hirai H, Thakur NK et al. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001; 104: 376-379.
20. Mansourati J, Newman LG, Roman SH, Travis A, Rafey M, Phillips RA. Lipid lowering does not improve endothelial function in subjects with poorly controlled diabetes. Diabetes Care 2001; 24: 2152-2153.
21. van Etten RW, de Koning EJ, Honing ML, Stroes ES, Gaillard CA, Rabelink TJ. Intensive lipid lowering by statin therapy does not improve vasoreactivity in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 2002; 22: 799-804.
22. van de Ree MA, Huisman MV, de Man FH, van der Vijver JC, Meinders AE, Blauw GJ. Impaired endothelium-dependent vasodilation in type 2 diabetes mellitus and the lack of effect of simvastatin. Cardiovasc Res 2001; 52: 299-305.
23. Van Venrooij FV, Van De Ree MA, Bots ML, Stolk RP, Huisman MV, Banga JD. Aggressive lipid lowering does not improve endothelial function in Type 2 diabetes: The Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial. Diabetes Care 2002; 25: 1211-1216.
24. Tan KC, Chow WS, Tam SC, Ai VH, Lam CH, Lam KS. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab 2002; 87: 563-568.
25. Playford DA, Watts GF, Croft KD, Burke V. Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes. Atherosclerosis 2003; 168: 169-179.
26. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356-360.
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
28. Morris SJ, Shore AC. Skin blood flow responses to the iontophoresis of acetylcholine and sodium nitroprusside in man: possible mechanisms. J Physiol 1996; 496: 531-542.
29. Rayman G, Williams SA, Spencer PD, Smaje LH, Wise PH, Tooke JE. Impaired microvascular hyperaemic response to minor skin trauma in type I diabetes. Br Med J (Clin Res Ed) 1986; 292: 1295-1298.
30. Doshi SN, Naka KK, Payne N, Jones CJ, Ashton M, Lewis MJ et al. Flow-mediated dilatation following wrist and upper arm occlusion in humans: the contribution of nitric oxide. Clin Sci 2001; 101: 629-635.
31. Koller A, Kaley G. Prostaglandins mediate arteriolar dilation to increased blood flow velocity in skeletal muscle microcirculation. Circ Res 1990; 67: 529-534.
32. Avogaro A, Miola M, Favaro A, Gottardo L, Pacini G, Manzato E et al. Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. Eur J Clin Invest 2001; 31: 603-609.
33. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357: 905-910.
34. Fruchart JC, Staels B, Duriez P. The role of fibric acids in atherosclerosis. Curr Atheroscler Rep 2001; 3: 83-92.
35. Tooke JE, Hannemann MM. Adverse endothelial function and the insulin resistance syndrome. J Intern Med 2000; 247: 425-431.
36. Jaap AJ, Shore AC, Tooke JE. Relationship of insulin resistance to microvascular dysfunction in subjects with fasting hyperglycaemia. Diabetologia 1997; 40: 238-243.
37. Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M et al. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 1999; 104: 447-457.
38. Lim SC, Caballero AE, Smakowski P, LoGerfo FW, Horton ES, Veves A. Soluble intercellular adhesion molecule, vascular cell adhesion molecule, and impaired microvascular reactivity are early markers of vasculopathy in type 2 diabetic individuals without microalbuminuria. Diabetes Care 1999; 22: 1865-1870.
39. Capell WH, DeSouza CA, Poirier P, Bell ML, Stauffer BL, Weil KM et al. Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia. Arterioscler Thromb Vasc Biol 2003; 23: 307-313.
40. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-1135.
41. Muniyappa R, Xu R, Ram JL, Sowers JR. Inhibition of Rho protein stimulates iNOS expression in rat vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2000; 278: H1762-1768.
42. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999; 353: 983-984.
43. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001; 103: 1191-1193.
44. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol Recurrent Events (CARE) Invest Circulation 1999; 100: 230-235.
45. Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20: 556-562.
46. Pietsch A, Erl W, Lorenz RL. Lovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells. Biochem Pharmacol 1996; 52: 433-439.
47. Skrha J, Stulc T, Hilgertova J, Weiserova H, Kvasnicka J, Ceska R. Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes. Eur J Pharmacol 2004; 493: 183-189.
48. Athyros VG, Papageorgiou AA, Elisaf M, Mikhailidis DP. Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin 2003; 19: 615-617.
49. Sowers JR. Endothelial vasodilation effects of statins in type 2 diabetic patients: response to van Venrooij et al. Diabetes Care 2002; 25: 1242-1243.
50. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001; 44: 129-146.
51. Schmidt AM, Van SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84: 489-497.
52. Xu B, Chibber R, Ruggiero D, Kohner E, Ritter J, Ferro A. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J 2003; 17: 1289-1291.
53. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Medical 2001; 2: 205-207.